Texas Children's Cancer and Hematology Center

Clinical Trials and Novel Therapies

Vinblastine/Prednisone versus Single Therapy with Cytarabine for Langerhans Cell Histiocytosis (LCH)

The purpose of this research study is to compare previously used vinblastine/prednisone to single therapy with cytarabine for LCH.

Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders (NACHO COBI)

The purpose of this research study is to learn whether cobimetinib is safe and effective in subjects diagnosed with LCH, LCH-ND, RDD, JXG and ECD which may have a specific mutation called BRAF-V600E.

TCH Histiocytosis Biology Study (H-25667)

This study seeks to understand the biology of histiocytic disorders by analyzing tissue and clinical data from patients with histiocytic disorders. 

NACHO-BIO: Biology Study for Histiocytic Disorders

This study collects biological samples from patients with histiocytic disorders to understand the disease’s biology and identify biomarkers that could improve future diagnosis and treatment. 

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

This phase II trial tests the safety, side effects, best dose and activity of tovorafenib (DAY101) in treating patients with Langerhans cell histiocytosis that is growing, spreading, or getting worse (progressive), has come back (relapsed) after previous treatment, or does not respond to therapy (refractory).

Open-label Study of ELA026 in Participants with Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

The purpose of this study is to assess the safety, efficacy pharmacokinetics and pharmacodynamics of ELA026 in participants with sHLH.